Related Experiment Video
Updated: Aug 12, 2026
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Medulloblastoma: clinical and biologic aspects
R J Packer1, P Cogen, G Vezina
1Departments of Neurology, Pediatrics, 111 Michigan Avenue, NW, Washington, DC 20010, USA.
Abstract:
Medulloblastoma is the most common childhood primary CNS tumor, and treatment approaches have evolved over the past three decades. The biologic underpinnings of medulloblastoma are not fully characterized, but recent work has identified new, important directions for research. Stratification of patients with medulloblastoma into risk groups is the backbone of most ongoing therapeutic studies. Patients are usually characterized as being either average risk or poor risk, although an intermediate risk group may exist. Standard treatment for older children with medulloblastoma consists of radiation and, for most, chemotherapy. Children with nondisseminated disease at the time of diagnosis have been reported to have as high as an 80% five-year disease-free survival rate after treatment with reduced dose (2340 cGy) craniospinal irradiation, local boost radiation therapy (5500 cGy), and chemotherapy, given during and after radiation therapy. Preradiation chemotherapy has yet to be shown to be of benefit for children with medulloblastoma. Children with disseminated disease are a highly problematic subgroup of patients to treat. A variety of new approaches are being studied, most of which are intensifying chemotherapy either prior to or after radiation. Long-term survivors of medulloblastoma are at significant risk for permanent endocrinologic, cognitive, and psychological sequelae. Infants and very young children with medulloblastoma remain a difficult therapeutic challenge because they have the most virulent form of the disease and are at highest risk for treatment-related sequelae.
Insights
Medulloblastoma treatment has evolved, focusing on risk stratification and combining radiation with chemotherapy. While survival rates improve for some, long-term side effects and challenges in treating young children persist.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Biology
Background:
- Medulloblastoma is the most common primary central nervous system (CNS) tumor in children.
- Understanding the biology of medulloblastoma is crucial for developing new therapeutic strategies.
- Patient stratification into risk groups (average, poor, and potentially intermediate) is fundamental to current treatment studies.
Purpose of the Study:
- To review the evolution of medulloblastoma treatment over the past three decades.
- To highlight current therapeutic approaches, including risk stratification, radiation, and chemotherapy.
- To discuss challenges in treating specific patient subgroups, such as those with disseminated disease and very young children.
Main Methods:
- Review of current treatment protocols for medulloblastoma.
- Analysis of survival rates based on disease dissemination and patient age.
- Discussion of emerging research directions and challenges in managing treatment-related sequelae.
Main Results:
- Standard treatment for older children involves radiation and chemotherapy, with high survival rates (up to 80% 5-year disease-free survival) for nondisseminated disease using reduced-dose craniospinal irradiation.
- Preradiation chemotherapy has not demonstrated significant benefit.
- Children with disseminated disease and very young children represent challenging subgroups requiring intensified treatment approaches.
Conclusions:
- Treatment advancements have improved outcomes for some medulloblastoma patients, but challenges remain, particularly for infants and those with disseminated disease.
- Long-term survivors face significant risks of endocrinologic, cognitive, and psychological sequelae.
- Further research into the biology and novel therapeutic strategies is essential for improving outcomes and minimizing treatment toxicity.
